Get a glimpse into our company and investor data—powered by the PitchBook Platform
co.don AG in cell breeding for the joint-preserving treatment of articular cartilage damage. The company manufactures cell-based biological drugs for the use in orthopedic and neurosurgical applications. Its products are used for the treatment of focal cartilage defects, lumbar disc herniation, non-union fractures and dental disorders.
You’re viewing a free company profile from the PitchBook Platform. To explore co.don’s full profile, request a free trial.
52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
---|---|---|---|---|---|
$3.37 - $10.36 | $88.8M | $4.47 | -$0.49 | 16.9K | 19.5M |
In Thousands,
USD |
TTM
30-Jun-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
FY 2015
31-Dec-2015
|
---|---|---|---|---|
Enterprise Value | 106,590 | 154,857 | 42,653 | 46,813 |
Revenue | 7,081 | 6,726 | 6,192 | 5,642 |
EBITDA | (9,771) | (7,674) | (3,769) | (2,895) |
Net Income | (10,077) | (7,956) | (4,037) | (3,179) |
Total Assets | 32,745 | 22,734 | 4,452 | 8,861 |